1. Home
  2. RMCF vs NCEL Comparison

RMCF vs NCEL Comparison

Compare RMCF & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$0.96

Market Cap

14.9M

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$4.08

Market Cap

17.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
NCEL
Founded
1981
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
17.2M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
RMCF
NCEL
Price
$0.96
$4.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
170.0K
33.4K
Earning Date
06-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$1.83
52 Week High
$2.99
$5.12

Technical Indicators

Market Signals
Indicator
RMCF
NCEL
Relative Strength Index (RSI) 31.03 64.97
Support Level $0.84 $2.58
Resistance Level $1.19 $4.67
Average True Range (ATR) 0.12 0.40
MACD 0.01 0.00
Stochastic Oscillator 34.86 60.89

Price Performance

Historical Comparison
RMCF
NCEL

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: